Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial.

@article{Perez2017IntrinsicSA,
  title={Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial.},
  author={Edith A. Perez and Karla V. Ballman and Afshin Mashadi-Hossein and Kathleen S. Tenner and Jennifer M. Kachergus and Nadine Norton and Brian Necela and Jennifer M. Carr and Sean Ferree and Charles M. Perou and Frederick L. Baehner and Maggie Chon U. Cheang and E. Aubrey Thompson},
  journal={Journal of the National Cancer Institute},
  year={2017},
  volume={109 2},
  pages={1-8}
}
Background Genomic data from human epidermal growth factor receptor 2-positive (HER2+) tumors were analyzed to assess the association between intrinsic subtype and clinical outcome in a large, well-annotated patient cohort. Methods Samples from the NCCTG (Alliance) N9831 trial were analyzed using the Prosigna algorithm on the NanoString platform to define intrinsic subtype, risk of recurrence scores, and risk categories for 1392 HER2+ tumors. Subtypes were evaluated for recurrence-free… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS